Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection.

Hong ZhangYue HuMin WuJingrui LiuXiaoxue ZhuXiaojiao LiHong ChenCuiyun LiChengjiao LiuJunqi Niu Yanhua Ding

Published in: Alimentary pharmacology & therapeutics (2020)

HS-10234 was well tolerated during a 4-week course. TDF and HS-10234 had comparable potency in inhibiting HBV replication. A daily dose of 10-25 mg of HS-10234 is recommended for CHB treatment. (Chinese Drug Trial Identifier: CTR20161077).

Keyphrases

clinical trial
hepatitis b virus
study protocol
open label
phase iii
phase ii
physical activity
signaling pathway
emergency department
antiretroviral therapy
liver failure
replacement therapy
adverse drug
liver fibrosis